Comparison
A comparison of the approved dual agonist and the investigational triple agonist that is already sold gray-market.
Tirzepatide is the established, regulator-reviewed option; retatrutide has striking phase 2 weight-loss numbers but no approved product and an active gray market.
Tirzepatide, by a wide margin: multiple completed phase 3 programs and full FDA review behind labeled uses. Retatrutide's best data are a 48-week phase 2 study plus topline phase 3 announcements: promising, but the regulator-reviewed package does not exist yet.
Tirzepatide hits GIP and GLP-1; retatrutide adds glucagon agonism, which likely contributes to its larger phase 2 weight-loss numbers and its own side-effect discussion, including glucagon-related heart-rate increases. In phase 2, retatrutide's weight-loss curve had not clearly plateaued at 48 weeks.
There is no approved retatrutide product anywhere, so every vial sold today is unverified research-market material. Community schedules loosely imitate trial titration without the trial's drug, monitoring, or endpoints, and FDA has warned online sellers of the molecule.
| Dimension | Retatrutide | Tirzepatide |
|---|---|---|
| Overall evidence grade | B | A |
| Evidence label | Moderate human evidence | Strong human evidence |
| Regulatory status | Investigational / not approved | Approved for specific use |
| Editorial confidence | Moderate confidence | Moderate confidence |
| Efficacy | 5/5 strong | 5/5 strong |
| Safety | 3/5 emerging | 4/5 substantial |
| Regulatory risk | 3/5 moderate | 1/5 low |
| Product quality risk | 5/5 very high | 1/5 low |
| Primary claim categories | Weight management, Type 2 diabetes, Cardiometabolic risk markers, Gray-market quality risk | Weight management, Type 2 diabetes, OSA with obesity, FDA-approved product comparison |
Retatrutide has substantial clinical-development evidence, but trial results, sponsor updates, approval status, and online RETA product claims remain separate questions.
Tirzepatide has FDA-approved product labels for specific uses; compounded, clinic, gray-market, or off-label marketing claims need separate support.
PubMed. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial 2023.
doi:10.1056/NEJMoa2301972 PMID:37366315 Accessed 2026-06-09.
Primary peer-reviewed phase 2 trial in adults with obesity or overweight; supports the main human obesity evidence.
Other. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial 2026.
Accessed 2026-06-09.
Sponsor topline release for TRIUMPH-1; useful as current sponsor context, not a substitute for peer-reviewed publication or regulatory label review.
ClinicalTrials.gov. TRIUMPH-1 ClinicalTrials.gov record 2026.
NCT05929066 Accessed 2026-06-09.
Registry record for the phase 3 obesity/overweight TRIUMPH-1 trial.
FDA. FDA Approves New Medication for Chronic Weight Management 2023.
Accessed 2026-06-08.
FDA approval announcement for Zepbound, a tirzepatide product for chronic weight management in specified adults.